- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00988325
A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
30. Januar 2017 aktualisiert von: Hoffmann-La Roche
An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed Influenza Infection
This study will assess the pharmacokinetics/pharmacodynamics and safety of oseltamivir [Tamiflu] therapy in infants less than 1 year of age with influenza diagnosed in the 96 hours prior to the first dose.
Patients age 3-12 months will receive 3 mg/kg, 1-3 months will receive 2.5 mg/kg, and birth to 1 month will receive 2 mg/kg twice a day for a total of 10 doses.
Patients positive for influenza virus on Day 6 will be eligible to receive continued study treatment for an additional 10 doses (5 days).
The anticipated time on study treatment is 4 weeks, and the target sample size is 65-85 male and female infants.
Studienübersicht
Studientyp
Interventionell
Einschreibung (Tatsächlich)
65
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Bruxelles, Belgien, 1200
- Cliniques Universitaires St-Luc
-
-
-
-
-
Berlin, Deutschland, 13353
- CAMPUS VIRCHOW-KLINIKUM CharitéCentrum 17 Klinik f.Pädiatrie Abt.Pneumologie u.Immunologie
-
Bochum, Deutschland, 44792
- LWL-Klinik-Bochum
-
Worms, Deutschland, 67547
- Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard & B. Reimann
-
-
-
-
-
Bron, Frankreich, 69677
- Hôpital Femme Mère Enfant; Service de rhumatologie pédiatrique
-
-
-
-
Lombardia
-
Milan, Lombardia, Italien, 20122
- Fondazione Ospedale Maggiore Policlinico
-
-
-
-
-
Bydgoszcz, Polen, 85-021
- VitaMed
-
Bydgoszcz, Polen, 85-168
- Samodzielny Publiczny Zakład Opieki; Wcześniaków I Intensywnej Terapii
-
Debica, Polen, 39-200
- Zespol Opieki Zdrowotnej Debica; Oddzial Dzieciecy
-
Trzebnica, Polen, 55-100
- St Hedwig Hospital In Trzebnica
-
-
-
-
-
Madrid, Spanien, 28905
- Hospital Universitario de Getafe; Servicio de Pediatria
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spanien, 15706
- Complejo Hospitalario Universitario de Santiago (CHUS) ; Intermedios y Urgencias Pediatricas
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
Nicht älter als 1 Jahr (Kind)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- infants </=12 months of age
- laboratory confirmed diagnosis of influenza within 96 hours prior to first dose
- influenza symptoms for </=96 hours prior to first dose
Exclusion Criteria:
- preterm infants less than 40 weeks (corrected for gestational age)
- weight less than 5th percentile for age (corrected for gestational age)
- concurrent gastrointestinal conditions that preclude enteric absorption of the drug
- bronchopulmonary dysplasia/chronic lung disease on assisted ventilation at time of enrollment
- active or uncontrolled respiratory, cardiac, hepatic, CNS or renal disease at baseline
- symptomatic inborn errors of metabolism
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Oseltamivir 3 mg
infants 3 to <12 months
|
oral repeating dose
|
Experimental: Oseltamivir 2.5 mg
infants 1 to <3 months of age
|
oral repeating dose
|
Experimental: Oseltamivir 2 mg
infants 0 to 30 days (post natal) of age
|
oral repeating dose
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
AUC0-12 was estimated for oseltamivir and oseltamivir carboxylate by linear trapezoidal rule
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Steady-state Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.
Cmax was estimated for both oseltamivir and Oseltamivir carboxylate by non-compartmental analysis.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Steady-state Minimum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
Cmin was estimated for both oseltamivir and oseltamivir carboxylate by non-compartmental analysis
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to the Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.Tmax was estimated using non-compartmental methods
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Apparent Elimination Half Life of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Elimination half-life is defined as the time required for elimination of a drug to half its plasma concentration and was computed using non-compartmental method
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Apparent First-order Elimination Rate Constant of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.The apparent first-order elimination rate constant (Lambda Z) was determined by linear regression analysis of terminal data points.
A minimum of 3 data points were used for lambda Z estimation.
By reporting tool convention, if n<3, no summary statistics were calculated
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Total Plasma Clearance as a Function of Bioavailability and Apparent Plasma Clearance of the Metabolite as a Function of Bioavailability (CLm/F) of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
CL/F was calculated as dose/AUCinf, where AUCinf represents the area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
The Volume of Distribution as a Function of Bioavailability of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Clast of Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
The last measurable plasma concentration of oseltamivir and oseltamivir carboxylate was the last quantifiable concentration of oseltamivir or oseltamivir carboxylate, respectively.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Time of the Last Measurable Plasma Concentration for Oseltamivir and Oseltamivir Carboxylate
Zeitfenster: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Number of Participants With Change From Baseline in Neurological Assessment Scores
Zeitfenster: Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30
|
Neurological assessment was performed to assess the mental state of the participants through two scales: Infant face scale and Glasgow coma scale.
Each scale consists of 3 subscales: eye opening (ranging 1 to 4), verbal response (ranging 1 to 5), and motor responses (ranging 1 to 6).
The final score is the sum of these ranges and is scored between 3 and 15. 3 being the worst, and 15 the best.
Change from baseline is change of final score post-baseline minus the final score at baseline.
|
Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30
|
Median Time to Cessation of Viral Shedding in Participants With Positive Culture at Baseline
Zeitfenster: Days 1, 3 or 4, 6, 11, 18, and 30
|
Median time to cessation of viral shedding was calculated for all patients with positive by culture / by polymerase chain reaction (PCR) at baseline using all data points between the start of the treatment and the 1st time point of negative culture without subsequent positive culture results.
These time-to event analyses were only performed for the viral titre.
|
Days 1, 3 or 4, 6, 11, 18, and 30
|
Number of Participants With Virus Shedding by Virus Type
Zeitfenster: Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
The viral titer was measured by culture and reported in log10 (50% tissue culture infective dose [TCID50]).
The viral load was analyzed by PCR and reported as log10 particles/mL.
The number of patients positive for viral shedding by virus sub-type was measured on specified days from baseline to last visit on Day 30.
|
Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
Time to Resolution of Fever in Participants With Fever at the Baseline
Zeitfenster: Days 1 to 11; Day 18; Day 30
|
This was performed for all participants who had fever at baseline.
Fever is defined as body temperature >37.0 degree Celsius.
Rectal temperature is converted by subtracting 1 degree Celsius.
Time to Resolution of Fever was defined as the time from the initiation of treatment to first time the afebrile state was reached and maintained for at least 21.5 hours, where afebrile state was defined as axillary temperature ≤ 37 degree Celsius.
|
Days 1 to 11; Day 18; Day 30
|
Percentage of Participants With Decline of Body Temperature to the Afebrile State
Zeitfenster: Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
This was performed for all participants who had fever at baseline Fever is defined as body temperature >37.0ºC.
Rectal temperature is converted by subtracting 1 ºC.
The rate of decline of body temperature was calculated as the slope of body temperature between the baseline temperature and the 1st temperature below 37°C.
Participants with decline in body temperature were considered to have no fever; however, participants who did not show any decline in body temperature were considered to have persisting fever.
|
Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
Number of Participants With Adverse Events, Serious Adverse Events and Secondary Illness
Zeitfenster: Up to 3 days after the last dose of oseltamivir (Approximately 14 days)
|
An Adverse Event (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product.
An Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
Secondary illnesses were influenza disease-related events, namely bronchitis, pneumonia, otitis media, and sinusitis that resolved without sequelae.
Adverse events, serious adverse events, and secondary illness are reported for on-treatment period (from the first dose of oseltamivir upto 3 days after the last dose of oseltamivir [Approximately 14 days].
|
Up to 3 days after the last dose of oseltamivir (Approximately 14 days)
|
Number of Participants Showing Within-patient Variability in Vital Signs
Zeitfenster: Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days
|
Systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and heart rate were examined for any consistent within-patient post-baseline changes.
|
Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Januar 2011
Primärer Abschluss (Tatsächlich)
1. April 2012
Studienabschluss (Tatsächlich)
1. April 2012
Studienanmeldedaten
Zuerst eingereicht
30. September 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
30. September 2009
Zuerst gepostet (Schätzen)
2. Oktober 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
20. März 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
30. Januar 2017
Zuletzt verifiziert
1. Januar 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- WP22849
- 2009-014365-12
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tamiflu
-
Chinese University of Hong KongFood and Health Bureau, Hong Kong; Hospital AuthorityBeendetGrippe | Infektionen der oberen AtemwegeChina, Hongkong
-
The Affiliated Hospital of Qingdao UniversityAbgeschlossenGesunde ProbandenChina
-
Hoffmann-La RocheAbgeschlossenGrippeAustralien, Hongkong, Vereinigte Staaten, Frankreich, Deutschland, Niederlande, Norwegen, Polen
-
Hoffmann-La RocheBeendetGrippeVereinigte Staaten, Israel
-
Trial Management Group Inc.Hoffmann-La RocheBeendet
-
Materia Medica HoldingAbgeschlossen
-
Hoffmann-La RocheBeendet
-
Hoffmann-La RocheAbgeschlossenGrippeVereinigte Staaten, Libanon, Israel
-
Materia Medica HoldingAbgeschlossenGrippeRussische Föderation
-
Hoffmann-La RocheBeendet